| Advanced therapies like CAR-T have been in the news for their potential to fundamentally change and personalize cancer treatment. Manufacturing these therapies is hard. Overcoming key bottlenecks is essential to commercial viability. The cost and variability associated with these personalized advanced therapies presents a critical manufacturing and translational challenge. The current clinical pipeline in this field shows the imminent need for manufacturing optimization. However, current manufacturing protocols are limited in terms of their scalability and cost-effectiveness.
Watch this webinar to learn about: Consistent and scalable expansion of CAR-T cells in stirred-tank bioreactors Reducing variability Establishing a control strategy for CAR-T process intensification | 